1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Toll-free: 800.544.0155
All Contents © 2017The Kiplinger Washington Editors
Sometimes bad news is good news. A pummeling of biotechnology stocks over the past year means that gutsy investors can get in on a formerly high-flying sector at discounted prices. From its peak in...
The market's best mutual funds are going to have to be able to navigate a brutal 2016 environment.
Stocks should end the year with modest gains. We show you how to boost your returns by focusing on value stocks and companies that raise their dividends.
More Investing News »